{"gene":"CCL22","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1997,"finding":"CCL22 (STCP-1) is a CC chemokine that induces Ca2+ mobilization and acts as a potent chemoattractant specifically for chronically activated T lymphocytes, but not for monocytes, neutrophils, eosinophils, or resting T lymphocytes.","method":"Molecular cloning from activated macrophage cDNA library; Ca2+ mobilization assay; in vitro chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — original cloning paper with in vitro functional reconstitution (Ca2+ flux, chemotaxis) across multiple cell types, establishing selectivity","pmids":["9312138"],"is_preprint":false},{"year":1998,"finding":"CCL22 (STCP-1) acts specifically on Th2 memory CD4+ lymphocytes via CCR4; TARC (CCL17) and STCP-1 share CCR4 as a common receptor, demonstrated by cross-desensitization in Ca2+ flux experiments. CCL22 is produced constitutively by dendritic cells, B cells, and macrophages, and its production is upregulated by IL-4 and IL-13 and inhibited by IL-10.","method":"Ca2+ flux desensitization assay; in vitro T cell subset chemotaxis; cytokine stimulation of producer cells with ELISA","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — receptor identification via cross-desensitization, multiple cell types tested, replicated by subsequent work","pmids":["9794440"],"is_preprint":false},{"year":2001,"finding":"Dendritic cells are the predominant source of CCL22 among leukocytes; DC maturation signals (LPS, IL-1, TNF, CD40L, bacteria/yeast recognition) dramatically increase CCL22 production. Mass spectrometry of DC supernatants identified N-terminally truncated forms CCL22(3-69), CCL22(5-69), and CCL22(7-69) that do not recognize CCR4, suggesting a negative feedback regulatory mechanism.","method":"ELISA; mass spectrometry of DC supernatants; in vitro DC stimulation assays; immunohistochemistry","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mass spectrometry identification of truncated forms with functional inference (CCR4 non-recognition), multiple stimuli tested, in vivo confirmation by IHC","pmids":["11241286"],"is_preprint":false},{"year":2001,"finding":"CCL22 and its receptor CCR4 are involved in the formation of T lymphocyte–dendritic cell clusters in inflamed skin and secondary lymphoid tissue; CCL22 is produced by DCs in T cell zones, and CCR4 is expressed on approximately one-third of CD4+ T cells in inflamed skin.","method":"RT-PCR; immunohistochemistry; cell-type identification in human tissue","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single-lab IHC and RT-PCR in human tissue, multiple tissue types examined, no functional blocking experiment","pmids":["11290544"],"is_preprint":false},{"year":2001,"finding":"Intestinal epithelial cells constitutively produce CCL22, and NF-κB activation is required for CCL22 expression in response to proinflammatory cytokines or enteroinvasive bacteria. CCL22 secreted from the basolateral side of polarized epithelial cells induces CCR4+ T cell chemotaxis.","method":"RT-PCR; ELISA; NF-κB inhibition assay; polarized epithelial cell chemotaxis assay","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — NF-κB requirement established by inhibitor + functional chemotaxis assay, polarized secretion demonstrated, single lab","pmids":["11352815"],"is_preprint":false},{"year":2002,"finding":"CD40 ligation of CLL B cells induces CCL22 mRNA expression and protein secretion; secreted CCL22 recruits activated CD4+CD40L+ T cells via CCR4, and this migration is abrogated by anti-CCL22 antibodies.","method":"RT-PCR; ELISA; neutralizing antibody migration assay; immunohistochemistry","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody neutralization of migration confirms CCL22 specificity, CD40 ligand identified as inducer, single lab","pmids":["11981828"],"is_preprint":false},{"year":2002,"finding":"IFN-γ stimulates primary epidermal keratinocytes to express CCL22 mRNA and protein; CCL22 immunoreactivity is present in the epidermal layer of atopic dermatitis skin, suggesting post-transcriptional regulation distinguishes CCL22 from CCL17 production in these cells.","method":"ELISA; RT-PCR; immunohistochemistry of human AD skin; primary keratinocyte stimulation","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary human cells used, in vivo IHC correlating with in vitro, single lab","pmids":["12096036"],"is_preprint":false},{"year":2002,"finding":"Activated microglia produce bioactive CCL22 that induces chemotaxis of Th2 but not Th1 cells; CCL22 and CCR4 mRNAs are expressed in the CNS of EAE mice, with CCL22 produced by CNS-infiltrating leukocytes and intraparenchymal microglia.","method":"In vitro microglia activation; Th1/Th2 chemotaxis assay; immunohistochemistry; RT-PCR in EAE model","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional bioactive CCL22 from microglia confirmed by chemotaxis, in vivo expression in EAE, single lab","pmids":["12225884"],"is_preprint":false},{"year":2004,"finding":"CCL22 is a potent and rapid inducer of CCR4 internalization on human Th2 cells via lipid raft- and clathrin-coated pit-dependent mechanisms, independent of G protein coupling. CCL17 does not induce CCR4 internalization. CCR4 internalization leads to functional desensitization, which is reversed by receptor recycling to restore chemotactic responsiveness.","method":"Flow cytometry CCR4 internalization assay; pharmacological inhibitors (lipid raft disruption, clathrin inhibition, G protein uncoupling); chemotaxis recovery assays on human Th2 cells","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic dissection of receptor internalization with multiple pharmacological inhibitors, comparison with CCL17, functional consequence (desensitization/recovery) established","pmids":["14971049"],"is_preprint":false},{"year":2004,"finding":"Latent membrane protein 1 (LMP1) of EBV induces CCL22 expression in B cells via NF-κB and ATF2/p38 signaling pathways; transfection assays with CCL22 promoter-reporter constructs identified two NF-κB sites and one AP-1 site as required for LMP1-mediated CCL22 promoter activation.","method":"Transient transfection reporter assay with CCL22 promoter constructs; pathway inhibitors (BAY11-7082, SB202190); RT-PCR; ELISA","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Strong — promoter dissection with reporter constructs identifying specific NF-κB and AP-1 sites, corroborated with pharmacological inhibitors, single lab with multiple orthogonal methods","pmids":["14747532"],"is_preprint":false},{"year":2006,"finding":"CCL22 and CCL17 stimulate T cell migration via CCR4 through a phospholipase C (PLC)- and diacylglycerol/novel PKC isoform-dependent mechanism; PLC inhibition blocks both Ca2+ mobilization and chemotaxis. Specifically, CCL22 stimulates phosphatidylinositol-3 kinase-independent phosphorylation of PKCδ at Thr505, associated with increased catalytic activity. Inhibition of IP3 receptor-mediated Ca2+ release blocks Ca2+ responses but not directional migration.","method":"Pharmacological inhibitors of PLC, PKC isoforms, IP3R, PI3K; Ca2+ imaging; chemotaxis assay in CEM cells and primary Th2 cells; PKCδ phosphorylation by western blot","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal pharmacological dissections separating Ca2+ signaling from migration, specific PKCδ phosphorylation identified, two cell systems used","pmids":["16614259"],"is_preprint":false},{"year":2006,"finding":"RANKL stimulation induces CCL22 production in differentiating osteoclasts; CCL22 stimulates migration and invasion of CCR4-expressing lung cancer cells (SBC-5) and activates phosphorylation of Akt and ERK in these cells.","method":"RANKL stimulation of RAW264.7 and mouse bone marrow cells; RT-PCR; ELISA; migration assay; western blot (pAkt, pERK); immunohistochemistry of bone metastasis lesions","journal":"Clinical & experimental metastasis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RANKL identified as inducer in two osteoclast models, CCL22-stimulated Akt/ERK signaling shown in cancer cells, in vivo co-localization confirmed, single lab","pmids":["16821125"],"is_preprint":false},{"year":2008,"finding":"HCMV UL144 protein activates NF-κB to transcriptionally induce CCL22; although viral IE86 can block NF-κB binding to synthetic promoters, it is unable to block UL144-mediated activation of the CCL22 promoter, with CREB binding to the CCL22 promoter implicated in this resistance.","method":"Promoter-reporter transfection assays; co-expression of UL144 and IE86; EMSA/DNA binding analysis","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assays with specific viral proteins establish UL144/NF-κB/CCL22 axis and IE86 resistance, single lab","pmids":["18287226"],"is_preprint":false},{"year":2009,"finding":"CCL22 promotes formation of DC–regulatory T cell contacts through CCR4 in lymph nodes; CCL22 expression by DCs is required for proper Treg–DC interaction. In CCL22-deficient mice, vaccination leads to excessive T cell responses, and tumor-bearing CCL22-deficient mice show prolonged survival upon vaccination.","method":"CCL22-deficient mouse model; vaccination assays; tumor challenge; flow cytometry; live imaging of cell-cell contacts","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model with multiple functional readouts (vaccination response, tumor survival, cell contacts), replicated in multiple experimental settings","pmids":["30910796"],"is_preprint":false},{"year":2009,"finding":"CCL22 produced by tumor cells recruits CCR4-expressing regulatory T cells into breast tumor-associated lymphoid infiltrates; blood Tregs selectively express CCR4, and CCR4 is downregulated on tumor-infiltrating Tregs indicating receptor engagement by CCL22.","method":"Immunohistochemistry; flow cytometry; in vitro migration assay; CCR4 expression analysis on Tregs","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — migration assay plus CCR4 downregulation as evidence of in vivo engagement, correlation with CCL22 expression, single lab","pmids":["19244125"],"is_preprint":false},{"year":2009,"finding":"CCL22 level in malignant pleural effusion is chemotactic for CD4+CD25+FoxP3+ regulatory T cells; this chemotactic activity is partially blocked by anti-CCL22 antibody but not anti-CCL17 antibody. Intrapleural administration of CCL22 induces progressive influx of Tregs into the pleural space in vivo.","method":"In vitro Transwell migration assay with neutralizing antibody; in vivo intrapleural CCL22 administration; ELISA; flow cytometry","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody neutralization in vitro and in vivo CCL22 administration both confirm direct Treg recruitment, single lab","pmids":["19318474"],"is_preprint":false},{"year":2009,"finding":"In mesenteric lymph node DCs, phagocytosis of autologous apoptotic cells induces CCL22 expression; CCL22/CCR4 axis facilitates DC–Treg interactions that promote IDO expression in DCs via CTLA-4/B7. CCR4-deficient mice show markedly reduced IDO expression in MLN-DCs.","method":"CCR4-KO mouse model; apoptotic cell phagocytosis assay; IDO activity measurement; CTLA-4 conditional deletion in Tregs; colocalization analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO confirms CCL22/CCR4 requirement for IDO induction, apoptotic cell trigger identified, single lab","pmids":["19843945"],"is_preprint":false},{"year":2009,"finding":"TNF-α/IFN-γ-induced CCL22 production in HaCaT keratinocytes is mediated via NF-κB and STAT1 activation, with p38 MAPK acting upstream to regulate both pathways. The adenylyl cyclase–cAMP system suppresses CCL22 production by inhibiting NF-κB activation through the p38 MAPK pathway.","method":"Western blot; RT-PCR; ELISA; pharmacological inhibitors (p38, NF-κB, cAMP analogs, adenylyl cyclase activator)","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors converging on NF-κB/p38 mechanism, single lab, two stimulation systems tested","pmids":["19371952"],"is_preprint":false},{"year":2010,"finding":"CCL22 controls EAE development by regulating CD11b+Ly6Chi macrophage accumulation and effector function; anti-CCL22 neutralization reduces CNS macrophage infiltration and shifts macrophage cytokine expression from TNF-dominated (M1) to IL-10-dominated (M2) phenotype, both in vivo and in in vitro macrophage cultures treated with CCL22.","method":"Anti-CCL22 neutralizing antibody in EAE model; adoptive T cell transfer; flow cytometry; in vitro macrophage culture with CCL22","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro evidence for CCL22 direct action on macrophage phenotype, single lab, mechanistic follow-up in vitro","pmids":["20940325"],"is_preprint":false},{"year":2011,"finding":"Islet expression of CCL22 recruits endogenous Tregs to pancreatic islets and prevents autoimmune diabetes in NOD mice; the protective effect is abrogated by CD25-specific antibody depletion of Tregs. CCL22-mediated protection increases TGF-β levels in CD4+ T cells near islets and decreases autoreactive CD8+ T cells.","method":"AAV-mediated CCL22 gene delivery to islets; Treg depletion with anti-CD25 antibody; flow cytometry; cytokine measurement","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gene delivery with specific Treg depletion control confirms CCL22→Treg recruitment as the mechanistic axis, multiple readouts, peer-reviewed high-impact journal","pmids":["21737880"],"is_preprint":false},{"year":2011,"finding":"NK cells secrete CCL22 in the tumor microenvironment and are the predominant cellular source responsible for CCL22-dependent selective recruitment of CCR4+ regulatory T cells; NK cell depletion from lung tissue significantly reduces CCL22 secretion, and CCL22 neutralization reduces selective Treg recruitment.","method":"Immunomagnetic cell isolation; FACS; flow cytometry; NK cell depletion; CCL22 neutralization; migration assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — NK depletion and CCL22 neutralization both confirm the NK→CCL22→Treg axis, multiple methods, single lab","pmids":["19234170"],"is_preprint":false},{"year":2011,"finding":"CCL22 production by breast tumor cells is controlled by innate immune cell-derived signals: monocyte-derived IL-1β and TNF-α, combined with IFN-γ from NK cells, drive CCL22 secretion from tumor cells. Monocyte depletion or cytokine neutralization attenuates CCL22 secretion.","method":"Co-culture of breast tumor cell lines with PBMCs; monocyte depletion; cytokine neutralization; NK cell activation assays; ELISA","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — depletion and neutralization experiments identify IL-1β, TNF-α, and IFN-γ as required co-stimuli, single lab with multiple orthogonal approaches","pmids":["21852386"],"is_preprint":false},{"year":2012,"finding":"TGF-β suppresses miR-34a expression, leading to enhanced CCL22 production which recruits Treg cells to facilitate immune escape in HBV-associated hepatocellular carcinoma with portal vein tumor thrombus. TGF-β–miR-34a–CCL22 forms a regulatory axis.","method":"miRNA expression profiling; miR-34a overexpression/knockdown; TGF-β stimulation; ELISA; Treg migration assay","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistatic axis established with miR-34a manipulation and TGF-β stimulation, single lab, single paper","pmids":["22975373"],"is_preprint":false},{"year":2015,"finding":"IL-4-driven CCL22 production by local cells is required for CCR4+ Treg migration to osteolytic lesions in experimental periodontitis; CCR4-KO mice and CCL22 blockade both increase bone loss and proinflammatory cytokines. Exogenous CCL22 delivered via PLGA microparticles restores Treg migration and bone loss arrest in IL-4-KO mice that lack endogenous CCL22.","method":"CCR4-KO mice; anti-CCL22 antibody blockade; adoptive Treg transfer; PLGA microparticle CCL22 delivery in IL-4-KO mice; flow cytometry","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacological approaches (KO, blockade, adoptive transfer, exogenous delivery) all converge on IL-4/CCL22/CCR4 axis, single lab","pmids":["25264308"],"is_preprint":false},{"year":2015,"finding":"Type I IFN induced by TLR or RIG-I ligands suppresses intratumoral CCL22 levels, thereby blocking Treg immigration into tumors. Stable overexpression of CCL22 abrogates the anti-tumor effects of RLR/TLR ligand treatment, confirming that CCL22 suppression is the key downstream effector of type I IFN's Treg-blocking activity.","method":"In vivo TLR/RLR ligand treatment; CCL22 stable overexpression in tumors; flow cytometry of tumor-infiltrating Tregs; ELISA","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CCL22 overexpression rescue experiment directly establishes the type I IFN → CCL22 suppression → Treg blockade mechanistic sequence, single lab","pmids":["26432403"],"is_preprint":false},{"year":2016,"finding":"Cancer cell-derived IL-1α induces CCL22 production by intratumoral dendritic cells (not by cancer cells themselves); this is prevented by the IL-1 receptor antagonist anakinra or by IL-1α siRNA knockdown in tumor cells, leading to suppression of Treg migration.","method":"In vitro PBMC co-culture with tumor cells; IL-1 receptor antagonist; IL-1α siRNA knockdown; ELISA; Treg migration assay","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IL-1α identified as inducer by siRNA and anakinra blockade, paracrine mechanism to DCs established, single lab","pmids":["27757295"],"is_preprint":false},{"year":2016,"finding":"CCL22-specific T cells recognizing a HLA-A2-restricted signal-peptide-derived epitope can kill CCL22-expressing cancer cells and acute monocytic leukemia cells in a CCL22 expression-dependent manner; spontaneous CCL22-specific T cell responses exist in cancer patients.","method":"Peptide epitope stimulation of PBMCs; cytotoxicity assay; ELISPOT; tetramer enrichment/depletion; CCL22-dependent killing validation","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CCL22 signal-peptide presentation on MHC-I established functionally, CCL22-dependent killing confirmed by expression-matched controls, single lab","pmids":["27999757"],"is_preprint":false},{"year":2019,"finding":"TAM-derived TGF-β induces CCL22 expression in macrophages via c-Fos; CCL22 recruits Tregs into malignant pleural effusion; Treg-secreted IL-8 further induces TGF-β production from TAMs, creating a positive feedback immunosuppressive loop.","method":"Western blot for c-Fos; TGF-β stimulation of macrophages; CCL22 neutralization; Treg migration assay; IL-8 measurement","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — c-Fos as TGF-β downstream mediator of CCL22 expression is a specific mechanistic finding; feedback loop established by multiple ELISA/migration assays, single lab","pmids":["30928379"],"is_preprint":false},{"year":2019,"finding":"M2 macrophage-derived CCL22 promotes resistance of colorectal cancer cells to 5-FU by activating the PI3K/AKT pathway, inducing EMT, and inhibiting caspase-mediated apoptosis; neutralizing anti-CCL22 antibody abolishes these effects.","method":"M2 macrophage conditioned medium; neutralizing anti-CCL22 antibody; western blot (PI3K/AKT, EMT markers, caspase); cell migration/invasion assay; apoptosis assay","journal":"OncoTargets and therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody neutralization establishes CCL22 specificity; PI3K/AKT and EMT identified as downstream pathways, single lab","pmids":["31114248"],"is_preprint":false},{"year":2020,"finding":"Constitutive CCL22 expression in secondary lymphoid organs requires T cell-derived GM-CSF: DCs alone cannot produce CCL22, but coculture with T cells or T cell supernatants induces CCL22 secretion. Rag1-/- mice (lacking T cells) have low lymphoid CCL22, restored by adoptive T cell transfer or GM-CSF administration.","method":"DC-T cell coculture; T cell supernatant fractionation; cytokine neutralization; Rag1-KO mouse with adoptive transfer; GM-CSF administration","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (coculture, KO model, adoptive transfer, cytokine reconstitution) all identify T cell GM-CSF as required inducer of DC-derived CCL22","pmids":["32907996"],"is_preprint":false},{"year":2021,"finding":"Upon CD40 stimulation, GC B cells upregulate CCL22 (and CCL17); CCL22 engages CCR4 on follicular helper T (TFH) cells to attract them, promoting productive T cell help. Higher-affinity GC B cells express higher CCL22 levels, creating a feedback loop that preferentially recruits TFH help. Ablation of CCL22 (and CCL17) in B cells results in inefficient affinity maturation, reduced GC participation, and fewer bone-marrow plasma cells.","method":"Conditional B cell-specific CCL22/CCL17 knockout mice; competitive GC experiments; TFH cell imaging; GC B cell affinity analysis; plasma cell quantification","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic ablation in B cells with multiple orthogonal readouts (affinity maturation, GC participation, plasma cell output), competitive experiments in same GC, high-impact journal","pmids":["33597749"],"is_preprint":false},{"year":2021,"finding":"Toxoplasma gondii effector protein GRA28 is secreted into host cell nuclei and is required for CCL22 induction in human placental cells and monocytes; parasites lacking GRA28 produce reduced CCL22 and are impaired in dissemination in vivo.","method":"GRA28 deletion mutant parasite; GRA28 nuclear localization by imaging; CCL22 ELISA in human placental cells, monocyte lines, mouse immune cells in vitro and in vivo; parasite dissemination assay","journal":"mBio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic deletion of GRA28 and nuclear localization establish parasite effector-driven CCL22 induction, conserved in mouse, single lab","pmids":["34781732"],"is_preprint":false},{"year":2020,"finding":"CCL22 acts as a potent partial agonist at ACKR4 (atypical chemokine receptor 4), recruiting β-arrestin; this was identified in a systematic screen of all 43 human chemokines using a sensitive β-arrestin recruitment assay, extending the known receptor repertoire of CCL22 beyond CCR4 and ACKR2.","method":"β-arrestin recruitment assay; systematic screen of 43 chemokines against ACKR4","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic receptor screen with β-arrestin assay identifies new receptor pairing, single lab, partial agonist designation","pmids":["32480426"],"is_preprint":false},{"year":2022,"finding":"Somatic gain-of-function mutations in CCL22 are the hallmark of a subset of chronic lymphoproliferative disorder of NK cells (CLPD-NK); these mutations cause ligand-biased GPCR signaling by impairing β-arrestin recruitment to CCR4, reducing receptor internalization, resulting in increased cell chemotaxis in vitro and enhanced NK cell proliferation in vivo in transgenic IL-15 mice.","method":"Genomic sequencing; β-arrestin recruitment assay; receptor internalization assay; in vitro chemotaxis assay; in vivo transgenic mouse model","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — mechanistic dissection with multiple orthogonal assays (β-arrestin, internalization, chemotaxis, in vivo) establishing gain-of-function biased GPCR signaling as the molecular mechanism","pmids":["35513723"],"is_preprint":false},{"year":2022,"finding":"TAM-derived CCL22 activates diacylglycerol kinase α (DGKα) which acts as a signaling adaptor linking CCR4 to FAK; CCL22/CCR4 signaling activates intracellular Ca2+/PLC-γ1 axis to stimulate DGKα phosphorylation at Tyr335 and promotes DGKα translocation to the plasma membrane to assemble a DGKα/FAK signalosome, activating the FAK/AKT pathway.","method":"Co-immunoprecipitation; western blot (phospho-FAK, phospho-DGKα); PLC-γ1 inhibition; DGKα siRNA; Ca2+ imaging; subcellular fractionation; in vivo xenograft model with DGKα siRNA","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical reconstitution of signaling complex (DGKα/FAK), specific phosphorylation site identified, multiple orthogonal approaches, in vivo validation, single lab","pmids":["35962191"],"is_preprint":false},{"year":2024,"finding":"TAM-derived CCL22 activates DGKα to produce phosphatidic acid (PA), suppressing NOX4 activity and blocking cisplatin-induced ROS overproduction; CCL22 also activates DGKα/NF-κB to upregulate ABC transporters (ABCG4, ABCA3, ABCA5), lowering intratumoral cisplatin concentration. Both mechanisms contribute to cisplatin resistance in ESCC.","method":"Lipid profiling (PA measurement); NOX4 activity assay; ROS measurement; NF-κB reporter; ABC transporter RT-PCR/western blot; DGKα siRNA cholesterol-conjugate in vivo; xenograft models","journal":"Drug resistance updates","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two mechanistic branches (NOX4/ROS and ABC transporters via NF-κB) established with multiple biochemical assays and in vivo rescue, single lab extending prior study","pmids":["38387281"],"is_preprint":false},{"year":2021,"finding":"In vitro, CCL22 promotes polarization of tumor-associated macrophages (TAMs) toward the M2a macrophage phenotype (CD206high) in a cervical cancer co-culture model; CCL22 regulates CD206 expression as assessed by flow cytometry.","method":"Co-culture system; CCL22 modulation; flow cytometry for macrophage subset markers","journal":"Cells","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single in vitro co-culture system, single lab, limited mechanistic depth","pmids":["35805111"],"is_preprint":false}],"current_model":"CCL22 is a CC chemokine that signals primarily through its canonical receptor CCR4 (and also through ACKR2 and ACKR4) to recruit regulatory T cells, Th2 cells, and follicular helper T cells; upon CCR4 binding it activates a PLC/diacylglycerol/PKCδ-dependent migration pathway and triggers ligand-biased receptor internalization via clathrin/lipid rafts in a β-arrestin-dependent manner; downstream CCR4 signaling engages DGKα as a signaling adaptor that assembles a DGKα/FAK signalosome to activate FAK/AKT; its expression is transcriptionally controlled by NF-κB and STAT/AP-1 sites and is constitutively driven in lymphoid organs by T cell-derived GM-CSF acting on dendritic cells; somatic gain-of-function mutations that impair β-arrestin recruitment cause biased GPCR signaling with enhanced chemotaxis underlying NK cell lymphoproliferative disease; and in germinal centers, CD40-stimulated upregulation of CCL22 by GC B cells proportional to antigen-binding affinity creates a positive-feedback circuit that focuses follicular T cell help on high-affinity clones to drive antibody affinity maturation."},"narrative":{"mechanistic_narrative":"CCL22 is a CC chemokine that functions as a selective chemoattractant for chronically activated and Th2 memory CD4+ T lymphocytes, signaling through its receptor CCR4, which it shares with CCL17 [PMID:9312138, PMID:9794440]. CCR4 engagement triggers Ca2+ mobilization and drives directional migration through a phospholipase C/diacylglycerol/PKCδ-dependent pathway that is separable from IP3-mediated Ca2+ release [PMID:16614259]. CCL22 is also a potent and rapid inducer of CCR4 internalization via lipid raft- and clathrin-dependent mechanisms that produce functional desensitization, distinguishing it from CCL17 which does not internalize the receptor [PMID:14971049]. The principal in vivo role of CCL22 is to recruit CCR4+ regulatory T cells and orchestrate DC–Treg contacts: CCL22-deficient mice show exaggerated vaccination responses and improved tumor control, while CCL22 delivery recruits Tregs to autoimmune and inflammatory sites to enforce tolerance [PMID:30910796, PMID:21737880, PMID:25264308]. This Treg-recruiting axis is repeatedly co-opted in cancer, where tumor cells, dendritic cells, NK cells, and tumor-associated macrophages are induced to secrete CCL22 by signals including IL-1, TNF-α/IFN-γ, and TGF-β, thereby drawing immunosuppressive Tregs into tumors [PMID:19244125, PMID:19234170, PMID:21852386, PMID:30928379]. CCL22 expression is transcriptionally controlled by NF-κB together with STAT/AP-1 elements and is constitutively driven in lymphoid organs by T cell-derived GM-CSF acting on dendritic cells [PMID:11352815, PMID:14747532, PMID:32907996]. In germinal centers, CD40-stimulated upregulation of CCL22 by GC B cells in proportion to antigen affinity recruits follicular helper T cells to drive antibody affinity maturation [PMID:33597749]. Downstream of CCR4 in macrophages, CCL22 engages DGKα as a signaling adaptor that assembles a DGKα/FAK signalosome to activate FAK/AKT [PMID:35962191]. Somatic gain-of-function mutations in CCL22 that impair β-arrestin recruitment cause biased CCR4 signaling with reduced receptor internalization and enhanced chemotaxis, underlying a subset of chronic lymphoproliferative disorder of NK cells [PMID:35513723].","teleology":[{"year":1997,"claim":"Establishing that a newly cloned CC chemokine selectively attracts activated T cells defined CCL22's target-cell specificity, distinguishing it from chemokines acting on myeloid cells.","evidence":"Molecular cloning from activated macrophage cDNA with Ca2+ flux and in vitro chemotaxis across multiple leukocyte types","pmids":["9312138"],"confidence":"High","gaps":["Receptor not yet identified","Signaling pathway downstream of Ca2+ flux unknown"]},{"year":1998,"claim":"Identifying CCR4 as the shared receptor for CCL22 and CCL17 and linking CCL22 to Th2 memory cells defined the receptor axis and cytokine regulation of its production.","evidence":"Ca2+ flux cross-desensitization, T cell subset chemotaxis, and cytokine stimulation of producer cells","pmids":["9794440"],"confidence":"High","gaps":["Intracellular signaling downstream of CCR4 not dissected","Receptor pairing with atypical receptors unaddressed"]},{"year":2001,"claim":"Identifying NF-κB-dependent transcription and N-terminally truncated inactive CCL22 forms established both the inducible expression control and a post-translational negative-feedback mechanism.","evidence":"ELISA, mass spectrometry of DC supernatants, NF-κB inhibition, and polarized epithelial chemotaxis assays","pmids":["11241286","11352815"],"confidence":"Medium","gaps":["Protease generating truncated forms not identified","Promoter elements not yet mapped"]},{"year":2004,"claim":"Showing that CCL22 (but not CCL17) drives rapid clathrin/lipid raft-dependent CCR4 internalization and desensitization revealed ligand-biased receptor regulation that tunes chemotactic responsiveness.","evidence":"Flow cytometry internalization assays with pharmacological inhibitors and chemotaxis recovery on human Th2 cells","pmids":["14971049"],"confidence":"High","gaps":["β-arrestin dependence not directly tested at this stage","Structural basis of ligand bias unknown"]},{"year":2004,"claim":"Promoter dissection identifying specific NF-κB and AP-1 sites driven by viral LMP1 defined the cis-regulatory architecture of CCL22 transcription.","evidence":"CCL22 promoter-reporter constructs with pathway inhibitors in B cells","pmids":["14747532"],"confidence":"High","gaps":["Endogenous (non-viral) activators of these sites not fully mapped here","Cell-type-specific enhancer usage unaddressed"]},{"year":2006,"claim":"Separating Ca2+ signaling from migration and identifying PKCδ Thr505 phosphorylation defined the molecular pathway converting CCR4 engagement into directional movement.","evidence":"Pharmacological dissection of PLC/PKC/IP3R/PI3K with Ca2+ imaging and chemotaxis in CEM and primary Th2 cells","pmids":["16614259"],"confidence":"High","gaps":["Link between PKCδ and cytoskeletal effectors not defined","Connection to later DGKα/FAK signalosome not established at this time"]},{"year":2009,"claim":"Genetic loss of CCL22 in mice and Treg recruitment assays established the in vivo physiological role of CCL22 in DC–Treg contact and tolerance, with consequences for vaccination and tumor immunity.","evidence":"CCL22-deficient and CCR4-KO mouse models, vaccination, tumor challenge, IDO induction, and Treg migration assays","pmids":["30910796","19244125","19318474","19843945"],"confidence":"High","gaps":["Quantitative contribution of CCL22 versus CCL17 in vivo not fully separated","Downstream tolerance mediators only partially mapped"]},{"year":2011,"claim":"Demonstrating that islet or NK-cell-derived CCL22 recruits Tregs to confer tissue protection established the therapeutic and tumor-microenvironment relevance of the CCL22→Treg axis.","evidence":"AAV CCL22 gene delivery with anti-CD25 Treg depletion in NOD mice and NK depletion/CCL22 neutralization in tumor models","pmids":["21737880","19234170"],"confidence":"High","gaps":["Cellular source hierarchy across tissues not unified","Duration and reversibility of Treg recruitment unaddressed"]},{"year":2016,"claim":"Mapping the cytokine inputs (IL-1, TNF-α, IFN-γ, TGF-β/miR-34a, type I IFN) that induce or suppress CCL22 across tumor cells, DCs, and macrophages defined the regulatory network governing intratumoral CCL22 levels.","evidence":"Co-culture, cytokine neutralization, siRNA, miR-34a manipulation, and CCL22 overexpression rescue across multiple tumor systems","pmids":["21852386","22975373","26432403","27757295"],"confidence":"Medium","gaps":["Relative weighting of inducers in human tumors unclear","Single-lab findings for several individual axes"]},{"year":2020,"claim":"Identifying T cell-derived GM-CSF as the required inducer of constitutive DC-derived CCL22 and identifying ACKR4 as an additional receptor refined both the homeostatic source control and the receptor repertoire of CCL22.","evidence":"DC–T cell coculture, Rag1-KO with adoptive transfer and GM-CSF reconstitution; systematic 43-chemokine β-arrestin screen against ACKR4","pmids":["32907996","32480426"],"confidence":"Medium","gaps":["Functional consequence of ACKR4 partial agonism in vivo unknown","GM-CSF signaling pathway to CCL22 promoter not mapped"]},{"year":2021,"claim":"B cell-specific ablation in germinal centers showed CCL22 recruits TFH help in proportion to B cell affinity, establishing a positive-feedback circuit driving antibody affinity maturation.","evidence":"Conditional B cell CCL22/CCL17 knockout, competitive GC experiments, TFH imaging, and plasma cell quantification","pmids":["33597749"],"confidence":"High","gaps":["Contribution of CCL22 alone versus combined with CCL17 not fully separated","Affinity-to-CCL22 transcriptional coupling mechanism unknown"]},{"year":2022,"claim":"Biochemical reconstitution of a DGKα/FAK signalosome and discovery of β-arrestin-impairing gain-of-function mutations defined a downstream effector pathway and a disease mechanism of biased CCR4 signaling.","evidence":"Co-IP, phospho-site mapping, DGKα siRNA, and xenografts; genomic sequencing with β-arrestin, internalization, chemotaxis, and IL-15 transgenic mouse assays","pmids":["35962191","35513723"],"confidence":"High","gaps":["Whether DGKα/FAK operates in T cells as in macrophages unaddressed","Structural basis linking mutations to β-arrestin loss not resolved"]},{"year":2024,"claim":"Linking CCL22/DGKα to phosphatidic acid-mediated NOX4 suppression and NF-κB-driven ABC transporter upregulation defined a mechanism of chemoresistance downstream of CCL22 signaling.","evidence":"Lipid profiling, NOX4/ROS assays, NF-κB reporter, ABC transporter expression, and DGKα siRNA xenografts","pmids":["38387281"],"confidence":"Medium","gaps":["Generalizability beyond ESCC unknown","Relative contribution of the two branches to resistance not quantified"]},{"year":null,"claim":"How CCL22 transcriptional output is quantitatively coupled to antigen affinity in GC B cells, and whether ACKR2/ACKR4 scavenging shapes CCL22 gradients in vivo, remain open.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of CCL22–CCR4/ACKR4 complexes","In vivo role of atypical receptor binding uncharacterized","Mechanism coupling B cell affinity to CCL22 levels unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,8,10,33]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,33]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,2]}],"pathway":[{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,1,3,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,19,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,34]}],"complexes":[],"partners":["CCR4","ACKR4","DGKA"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00626","full_name":"C-C motif chemokine 22","aliases":["CC chemokine STCP-1","MDC(1-69)","Macrophage-derived chemokine","Small-inducible cytokine A22","Stimulated T-cell chemotactic protein 1"],"length_aa":93,"mass_kda":10.6,"function":"May play a role in the trafficking of activated/effector T-lymphocytes to inflammatory sites and other aspects of activated T-lymphocyte physiology. Chemotactic for monocytes, dendritic cells and natural killer cells. Mild chemoattractant for primary activated T-lymphocytes and a potent chemoattractant for chronically activated T-lymphocytes but has no chemoattractant activity for neutrophils, eosinophils, and resting T-lymphocytes. Binds to CCR4. Processed forms MDC(3-69), MDC(5-69) and MDC(7-69) seem not be active","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O00626/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL22","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL22","total_profiled":1310},"omim":[{"mim_id":"612308","title":"ZINC FINGER AND BTB DOMAIN-CONTAINING 4; ZBTB4","url":"https://www.omim.org/entry/612308"},{"mim_id":"607884","title":"CKLF-LIKE MARVEL TRANSMEMBRANE DOMAIN-CONTAINING 1; CMTM1","url":"https://www.omim.org/entry/607884"},{"mim_id":"607003","title":"THYMIC STROMAL LYMPHOPOIETIN; TSLP","url":"https://www.omim.org/entry/607003"},{"mim_id":"604836","title":"CHEMOKINE, CC MOTIF, RECEPTOR 4; CCR4","url":"https://www.omim.org/entry/604836"},{"mim_id":"602957","title":"CHEMOKINE, CC MOTIF, LIGAND 22; CCL22","url":"https://www.omim.org/entry/602957"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":13.8},{"tissue":"skin 1","ntpm":6.2}],"url":"https://www.proteinatlas.org/search/CCL22"},"hgnc":{"alias_symbol":["MDC","STCP-1","ABCD-1","DC/B-CK","A-152E5.1","MGC34554"],"prev_symbol":["SCYA22"]},"alphafold":{"accession":"O00626","domains":[{"cath_id":"2.40.50.40","chopping":"35-93","consensus_level":"high","plddt":96.0453,"start":35,"end":93}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00626","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00626-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00626-F1-predicted_aligned_error_v6.png","plddt_mean":87.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL22","jax_strain_url":"https://www.jax.org/strain/search?query=CCL22"},"sequence":{"accession":"O00626","fasta_url":"https://rest.uniprot.org/uniprotkb/O00626.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00626/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00626"}},"corpus_meta":[{"pmid":"19244125","id":"PMC_19244125","title":"Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19244125","citation_count":588,"is_preprint":false},{"pmid":"22975373","id":"PMC_22975373","title":"TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma.","date":"2012","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/22975373","citation_count":473,"is_preprint":false},{"pmid":"18224687","id":"PMC_18224687","title":"CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18224687","citation_count":317,"is_preprint":false},{"pmid":"11241286","id":"PMC_11241286","title":"Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11241286","citation_count":209,"is_preprint":false},{"pmid":"11981828","id":"PMC_11981828","title":"Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11981828","citation_count":207,"is_preprint":false},{"pmid":"9794440","id":"PMC_9794440","title":"STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9794440","citation_count":206,"is_preprint":false},{"pmid":"30910796","id":"PMC_30910796","title":"CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30910796","citation_count":205,"is_preprint":false},{"pmid":"15113590","id":"PMC_15113590","title":"Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis.","date":"2004","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/15113590","citation_count":156,"is_preprint":false},{"pmid":"30928379","id":"PMC_30928379","title":"Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30928379","citation_count":156,"is_preprint":false},{"pmid":"14747532","id":"PMC_14747532","title":"Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus.","date":"2004","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/14747532","citation_count":149,"is_preprint":false},{"pmid":"12096036","id":"PMC_12096036","title":"IFN-gamma-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis.","date":"2002","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12096036","citation_count":136,"is_preprint":false},{"pmid":"19630858","id":"PMC_19630858","title":"Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation.","date":"2009","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/19630858","citation_count":125,"is_preprint":false},{"pmid":"29099057","id":"PMC_29099057","title":"The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29099057","citation_count":108,"is_preprint":false},{"pmid":"21852386","id":"PMC_21852386","title":"Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21852386","citation_count":106,"is_preprint":false},{"pmid":"28039457","id":"PMC_28039457","title":"Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28039457","citation_count":102,"is_preprint":false},{"pmid":"14971049","id":"PMC_14971049","title":"Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14971049","citation_count":98,"is_preprint":false},{"pmid":"21737880","id":"PMC_21737880","title":"Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets.","date":"2011","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21737880","citation_count":90,"is_preprint":false},{"pmid":"12225884","id":"PMC_12225884","title":"Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation.","date":"2002","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/12225884","citation_count":87,"is_preprint":false},{"pmid":"22227193","id":"PMC_22227193","title":"Casuarinin suppresses TARC/CCL17 and MDC/CCL22 production via blockade of NF-κB and STAT1 activation in HaCaT cells.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22227193","citation_count":85,"is_preprint":false},{"pmid":"16556265","id":"PMC_16556265","title":"Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells.","date":"2006","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16556265","citation_count":85,"is_preprint":false},{"pmid":"25264308","id":"PMC_25264308","title":"IL-4/CCL22/CCR4 axis controls regulatory T-cell migration that suppresses inflammatory bone loss in murine experimental periodontitis.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25264308","citation_count":84,"is_preprint":false},{"pmid":"31114248","id":"PMC_31114248","title":"M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31114248","citation_count":84,"is_preprint":false},{"pmid":"9312138","id":"PMC_9312138","title":"Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9312138","citation_count":83,"is_preprint":false},{"pmid":"27757295","id":"PMC_27757295","title":"Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27757295","citation_count":83,"is_preprint":false},{"pmid":"11290544","id":"PMC_11290544","title":"Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11290544","citation_count":83,"is_preprint":false},{"pmid":"16821125","id":"PMC_16821125","title":"RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4.","date":"2006","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/16821125","citation_count":80,"is_preprint":false},{"pmid":"19715610","id":"PMC_19715610","title":"Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.","date":"2009","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/19715610","citation_count":76,"is_preprint":false},{"pmid":"20002703","id":"PMC_20002703","title":"CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma.","date":"2009","source":"Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus","url":"https://pubmed.ncbi.nlm.nih.gov/20002703","citation_count":76,"is_preprint":false},{"pmid":"19318474","id":"PMC_19318474","title":"CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19318474","citation_count":74,"is_preprint":false},{"pmid":"11339505","id":"PMC_11339505","title":"Stem cell factor and igE-stimulated murine mast cells produce chemokines (CCL2, CCL17, CCL22) and express chemokine receptors.","date":"2001","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/11339505","citation_count":73,"is_preprint":false},{"pmid":"19234170","id":"PMC_19234170","title":"NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19234170","citation_count":73,"is_preprint":false},{"pmid":"26432403","id":"PMC_26432403","title":"Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26432403","citation_count":70,"is_preprint":false},{"pmid":"19942450","id":"PMC_19942450","title":"Expression of MDC/CCL22 and its receptor CCR4 in rheumatoid arthritis, psoriatic arthritis and osteoarthritis.","date":"2009","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/19942450","citation_count":69,"is_preprint":false},{"pmid":"21129807","id":"PMC_21129807","title":"Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.","date":"2010","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/21129807","citation_count":69,"is_preprint":false},{"pmid":"19371952","id":"PMC_19371952","title":"The adenylyl cyclase-cAMP system suppresses TARC/CCL17 and MDC/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes.","date":"2009","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19371952","citation_count":68,"is_preprint":false},{"pmid":"12642832","id":"PMC_12642832","title":"Differential expression of thymus- and activation-regulated chemokine (CCL17) and macrophage-derived chemokine (CCL22) by human fibroblasts from cornea, skin, and lung.","date":"2003","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12642832","citation_count":67,"is_preprint":false},{"pmid":"25634358","id":"PMC_25634358","title":"CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.","date":"2015","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25634358","citation_count":66,"is_preprint":false},{"pmid":"23180648","id":"PMC_23180648","title":"Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23180648","citation_count":66,"is_preprint":false},{"pmid":"15293604","id":"PMC_15293604","title":"CCL22 and CCL17 in rat radiation pneumonitis and in human idiopathic pulmonary fibrosis.","date":"2004","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/15293604","citation_count":65,"is_preprint":false},{"pmid":"27775051","id":"PMC_27775051","title":"Fucoidan inhibits CCL22 production through NF-κB pathway in M2 macrophages: a potential therapeutic strategy for cancer.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27775051","citation_count":65,"is_preprint":false},{"pmid":"27999757","id":"PMC_27999757","title":"CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27999757","citation_count":65,"is_preprint":false},{"pmid":"19843945","id":"PMC_19843945","title":"Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19843945","citation_count":61,"is_preprint":false},{"pmid":"11352815","id":"PMC_11352815","title":"Production of MDC/CCL22 by human intestinal epithelial cells.","date":"2001","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11352815","citation_count":57,"is_preprint":false},{"pmid":"33597749","id":"PMC_33597749","title":"Affinity-coupled CCL22 promotes positive selection in germinal centres.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33597749","citation_count":55,"is_preprint":false},{"pmid":"30467506","id":"PMC_30467506","title":"CCL22-Producing Resident Macrophages Enhance T Cell Response in Sjögren's Syndrome.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30467506","citation_count":55,"is_preprint":false},{"pmid":"15993846","id":"PMC_15993846","title":"Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15993846","citation_count":55,"is_preprint":false},{"pmid":"25754123","id":"PMC_25754123","title":"CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.","date":"2015","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/25754123","citation_count":53,"is_preprint":false},{"pmid":"27152707","id":"PMC_27152707","title":"Higher circulating levels of chemokines CXCL10, CCL20 and CCL22 in patients with ischemic heart disease.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/27152707","citation_count":53,"is_preprint":false},{"pmid":"15466387","id":"PMC_15466387","title":"Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15466387","citation_count":53,"is_preprint":false},{"pmid":"35962191","id":"PMC_35962191","title":"Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC).","date":"2022","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35962191","citation_count":51,"is_preprint":false},{"pmid":"14715413","id":"PMC_14715413","title":"Monocyte-derived dendritic cells exposed to Der p 1 allergen enhance the recruitment of Th2 cells: major involvement of the chemokines TARC/CCL17 and MDC/CCL22.","date":"2003","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/14715413","citation_count":51,"is_preprint":false},{"pmid":"31134686","id":"PMC_31134686","title":"Macrophage CCL22 expression in the tumor microenvironment and implications for survival in patients with squamous cell carcinoma of the tongue.","date":"2019","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31134686","citation_count":49,"is_preprint":false},{"pmid":"32060848","id":"PMC_32060848","title":"CCL22 Signaling in the Tumor Environment.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32060848","citation_count":48,"is_preprint":false},{"pmid":"20940325","id":"PMC_20940325","title":"CCL22 regulates experimental autoimmune encephalomyelitis by controlling inflammatory macrophage accumulation and effector function.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20940325","citation_count":47,"is_preprint":false},{"pmid":"25245466","id":"PMC_25245466","title":"The role of the CCL22-CCR4 axis in the metastasis of gastric cancer cells into omental milky spots.","date":"2014","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25245466","citation_count":47,"is_preprint":false},{"pmid":"31497210","id":"PMC_31497210","title":"Circ_0039569 promotes renal cell carcinoma growth and metastasis by regulating miR-34a-5p/CCL22.","date":"2019","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/31497210","citation_count":46,"is_preprint":false},{"pmid":"18271928","id":"PMC_18271928","title":"Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/18271928","citation_count":46,"is_preprint":false},{"pmid":"16453150","id":"PMC_16453150","title":"Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer.","date":"2006","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/16453150","citation_count":43,"is_preprint":false},{"pmid":"27634754","id":"PMC_27634754","title":"Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27634754","citation_count":41,"is_preprint":false},{"pmid":"19205012","id":"PMC_19205012","title":"Titanium induced production of chemokines CCL17/TARC and CCL22/MDC in human osteoclasts and osteoblasts.","date":"2010","source":"Journal of biomedical materials research. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19205012","citation_count":41,"is_preprint":false},{"pmid":"31616630","id":"PMC_31616630","title":"Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31616630","citation_count":40,"is_preprint":false},{"pmid":"21116791","id":"PMC_21116791","title":"Sulforaphane suppresses TARC/CCL17 and MDC/CCL22 expression through heme oxygenase-1 and NF-κB in human keratinocytes.","date":"2010","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/21116791","citation_count":39,"is_preprint":false},{"pmid":"25136780","id":"PMC_25136780","title":"Macrophage-derived chemokine (CCL22) is a novel mediator of lung inflammation following hemorrhage and resuscitation.","date":"2014","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/25136780","citation_count":39,"is_preprint":false},{"pmid":"20348247","id":"PMC_20348247","title":"The novel association of the chemokine CCL22 with abdominal aortic aneurysm.","date":"2010","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20348247","citation_count":39,"is_preprint":false},{"pmid":"16614259","id":"PMC_16614259","title":"Evidence that phospholipase-C-dependent, calcium-independent mechanisms are required for directional migration of T-lymphocytes in response to the CCR4 ligands CCL17 and CCL22.","date":"2006","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/16614259","citation_count":39,"is_preprint":false},{"pmid":"18287226","id":"PMC_18287226","title":"NF-kappaB-mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86.","date":"2008","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/18287226","citation_count":39,"is_preprint":false},{"pmid":"25604093","id":"PMC_25604093","title":"Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time.","date":"2015","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25604093","citation_count":38,"is_preprint":false},{"pmid":"35513723","id":"PMC_35513723","title":"CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.","date":"2022","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35513723","citation_count":37,"is_preprint":false},{"pmid":"35805111","id":"PMC_35805111","title":"CCL22-Polarized TAMs to M2a Macrophages in Cervical Cancer In Vitro Model.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35805111","citation_count":35,"is_preprint":false},{"pmid":"19450895","id":"PMC_19450895","title":"Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets.","date":"2009","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19450895","citation_count":34,"is_preprint":false},{"pmid":"25740943","id":"PMC_25740943","title":"Cellular mechanisms of CCL22-mediated attenuation of autoimmune diabetes.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25740943","citation_count":33,"is_preprint":false},{"pmid":"29107385","id":"PMC_29107385","title":"CCL2 conditionally determines CCL22-dependent Th2-accumulation during TGF-β-induced breast cancer progression.","date":"2017","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29107385","citation_count":33,"is_preprint":false},{"pmid":"25722218","id":"PMC_25722218","title":"Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25722218","citation_count":33,"is_preprint":false},{"pmid":"19594754","id":"PMC_19594754","title":"Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line.","date":"2009","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19594754","citation_count":32,"is_preprint":false},{"pmid":"26204512","id":"PMC_26204512","title":"S100B Up-Regulates Macrophage Production of IL1β and CCL22 and Influences Severity of Retinal Inflammation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26204512","citation_count":31,"is_preprint":false},{"pmid":"36052217","id":"PMC_36052217","title":"CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment.","date":"2022","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/36052217","citation_count":28,"is_preprint":false},{"pmid":"35025968","id":"PMC_35025968","title":"EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35025968","citation_count":26,"is_preprint":false},{"pmid":"35396377","id":"PMC_35396377","title":"circ_0004140 promotes LUAD tumor progression and immune resistance through circ_0004140/miR-1184/CCL22 axis.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35396377","citation_count":26,"is_preprint":false},{"pmid":"17911044","id":"PMC_17911044","title":"The role of CCL22/macrophage-derived chemokine in allergic rhinitis.","date":"2007","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/17911044","citation_count":26,"is_preprint":false},{"pmid":"34781732","id":"PMC_34781732","title":"Toxoplasma gondii GRA28 Is Required for Placenta-Specific Induction of the Regulatory Chemokine CCL22 in Human and Mouse.","date":"2021","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/34781732","citation_count":26,"is_preprint":false},{"pmid":"38387281","id":"PMC_38387281","title":"Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis.","date":"2024","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/38387281","citation_count":25,"is_preprint":false},{"pmid":"33264064","id":"PMC_33264064","title":"Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6.","date":"2021","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33264064","citation_count":25,"is_preprint":false},{"pmid":"32278046","id":"PMC_32278046","title":"CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32278046","citation_count":25,"is_preprint":false},{"pmid":"32428547","id":"PMC_32428547","title":"Radiation-Enhanced Expression of CCL22 in Nasopharyngeal Carcinoma is Associated With CCR4+ CD8 T Cell Recruitment.","date":"2020","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/32428547","citation_count":25,"is_preprint":false},{"pmid":"15054038","id":"PMC_15054038","title":"LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22).","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15054038","citation_count":25,"is_preprint":false},{"pmid":"20337996","id":"PMC_20337996","title":"CCL22 is involved in the recruitment of CD4+CD25 high T cells into tuberculous pleural effusions.","date":"2010","source":"Respirology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/20337996","citation_count":24,"is_preprint":false},{"pmid":"35176085","id":"PMC_35176085","title":"LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/35176085","citation_count":23,"is_preprint":false},{"pmid":"26423995","id":"PMC_26423995","title":"CCL22 Prevents Rejection of Mouse Islet Allografts and Induces Donor-Specific Tolerance.","date":"2015","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/26423995","citation_count":23,"is_preprint":false},{"pmid":"32480426","id":"PMC_32480426","title":"Systematic reassessment of chemokine-receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22.","date":"2020","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/32480426","citation_count":23,"is_preprint":false},{"pmid":"32907996","id":"PMC_32907996","title":"Constitutive Expression of CCL22 Is Mediated by T Cell-Derived GM-CSF.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32907996","citation_count":21,"is_preprint":false},{"pmid":"33777206","id":"PMC_33777206","title":"Macrophage CCL22 expression promotes lymphangiogenesis in patients with tongue squamous cell carcinoma via IL-4/STAT6 in the tumor microenvironment.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33777206","citation_count":21,"is_preprint":false},{"pmid":"31445808","id":"PMC_31445808","title":"Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate.","date":"2019","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31445808","citation_count":21,"is_preprint":false},{"pmid":"36969873","id":"PMC_36969873","title":"Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36969873","citation_count":21,"is_preprint":false},{"pmid":"18052724","id":"PMC_18052724","title":"Expression of chemokine receptor CCR4 and its ligands (CCL17 and CCL22) in murine contact hypersensitivity.","date":"2007","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/18052724","citation_count":20,"is_preprint":false},{"pmid":"25922986","id":"PMC_25922986","title":"Expression of CCL22 and Infiltration by Regulatory T Cells are Increased in the Decidua of Human Miscarriage Placentas.","date":"2015","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/25922986","citation_count":20,"is_preprint":false},{"pmid":"32179746","id":"PMC_32179746","title":"Elevated serum chemokine CCL22 levels in first-episode psychosis: associations with symptoms, peripheral immune state and in vivo brain glial cell function.","date":"2020","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32179746","citation_count":20,"is_preprint":false},{"pmid":"27499437","id":"PMC_27499437","title":"CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27499437","citation_count":19,"is_preprint":false},{"pmid":"25834353","id":"PMC_25834353","title":"Mechanism of Macrophage-Derived Chemokine/CCL22 Production by HaCaT Keratinocytes.","date":"2015","source":"Annals of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/25834353","citation_count":19,"is_preprint":false},{"pmid":"26892271","id":"PMC_26892271","title":"Inhibitory effect of a histamine 4 receptor antagonist on CCL17 and CCL22 production by monocyte-derived Langerhans cells in patients with atopic dermatitis.","date":"2016","source":"The Journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26892271","citation_count":19,"is_preprint":false},{"pmid":"32187823","id":"PMC_32187823","title":"HBV promotes the recruitment of IL-17 secreting T cells via chemokines CCL22 and CCL17.","date":"2020","source":"Liver international : official journal of the International Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/32187823","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55061,"output_tokens":9378,"usd":0.152926,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19840,"output_tokens":4459,"usd":0.105338,"stage2_stop_reason":"end_turn"},"total_usd":0.258264,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CCL22 (STCP-1) is a CC chemokine that induces Ca2+ mobilization and acts as a potent chemoattractant specifically for chronically activated T lymphocytes, but not for monocytes, neutrophils, eosinophils, or resting T lymphocytes.\",\n      \"method\": \"Molecular cloning from activated macrophage cDNA library; Ca2+ mobilization assay; in vitro chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — original cloning paper with in vitro functional reconstitution (Ca2+ flux, chemotaxis) across multiple cell types, establishing selectivity\",\n      \"pmids\": [\"9312138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCL22 (STCP-1) acts specifically on Th2 memory CD4+ lymphocytes via CCR4; TARC (CCL17) and STCP-1 share CCR4 as a common receptor, demonstrated by cross-desensitization in Ca2+ flux experiments. CCL22 is produced constitutively by dendritic cells, B cells, and macrophages, and its production is upregulated by IL-4 and IL-13 and inhibited by IL-10.\",\n      \"method\": \"Ca2+ flux desensitization assay; in vitro T cell subset chemotaxis; cytokine stimulation of producer cells with ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — receptor identification via cross-desensitization, multiple cell types tested, replicated by subsequent work\",\n      \"pmids\": [\"9794440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Dendritic cells are the predominant source of CCL22 among leukocytes; DC maturation signals (LPS, IL-1, TNF, CD40L, bacteria/yeast recognition) dramatically increase CCL22 production. Mass spectrometry of DC supernatants identified N-terminally truncated forms CCL22(3-69), CCL22(5-69), and CCL22(7-69) that do not recognize CCR4, suggesting a negative feedback regulatory mechanism.\",\n      \"method\": \"ELISA; mass spectrometry of DC supernatants; in vitro DC stimulation assays; immunohistochemistry\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry identification of truncated forms with functional inference (CCR4 non-recognition), multiple stimuli tested, in vivo confirmation by IHC\",\n      \"pmids\": [\"11241286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL22 and its receptor CCR4 are involved in the formation of T lymphocyte–dendritic cell clusters in inflamed skin and secondary lymphoid tissue; CCL22 is produced by DCs in T cell zones, and CCR4 is expressed on approximately one-third of CD4+ T cells in inflamed skin.\",\n      \"method\": \"RT-PCR; immunohistochemistry; cell-type identification in human tissue\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single-lab IHC and RT-PCR in human tissue, multiple tissue types examined, no functional blocking experiment\",\n      \"pmids\": [\"11290544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Intestinal epithelial cells constitutively produce CCL22, and NF-κB activation is required for CCL22 expression in response to proinflammatory cytokines or enteroinvasive bacteria. CCL22 secreted from the basolateral side of polarized epithelial cells induces CCR4+ T cell chemotaxis.\",\n      \"method\": \"RT-PCR; ELISA; NF-κB inhibition assay; polarized epithelial cell chemotaxis assay\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NF-κB requirement established by inhibitor + functional chemotaxis assay, polarized secretion demonstrated, single lab\",\n      \"pmids\": [\"11352815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD40 ligation of CLL B cells induces CCL22 mRNA expression and protein secretion; secreted CCL22 recruits activated CD4+CD40L+ T cells via CCR4, and this migration is abrogated by anti-CCL22 antibodies.\",\n      \"method\": \"RT-PCR; ELISA; neutralizing antibody migration assay; immunohistochemistry\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody neutralization of migration confirms CCL22 specificity, CD40 ligand identified as inducer, single lab\",\n      \"pmids\": [\"11981828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-γ stimulates primary epidermal keratinocytes to express CCL22 mRNA and protein; CCL22 immunoreactivity is present in the epidermal layer of atopic dermatitis skin, suggesting post-transcriptional regulation distinguishes CCL22 from CCL17 production in these cells.\",\n      \"method\": \"ELISA; RT-PCR; immunohistochemistry of human AD skin; primary keratinocyte stimulation\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary human cells used, in vivo IHC correlating with in vitro, single lab\",\n      \"pmids\": [\"12096036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Activated microglia produce bioactive CCL22 that induces chemotaxis of Th2 but not Th1 cells; CCL22 and CCR4 mRNAs are expressed in the CNS of EAE mice, with CCL22 produced by CNS-infiltrating leukocytes and intraparenchymal microglia.\",\n      \"method\": \"In vitro microglia activation; Th1/Th2 chemotaxis assay; immunohistochemistry; RT-PCR in EAE model\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional bioactive CCL22 from microglia confirmed by chemotaxis, in vivo expression in EAE, single lab\",\n      \"pmids\": [\"12225884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL22 is a potent and rapid inducer of CCR4 internalization on human Th2 cells via lipid raft- and clathrin-coated pit-dependent mechanisms, independent of G protein coupling. CCL17 does not induce CCR4 internalization. CCR4 internalization leads to functional desensitization, which is reversed by receptor recycling to restore chemotactic responsiveness.\",\n      \"method\": \"Flow cytometry CCR4 internalization assay; pharmacological inhibitors (lipid raft disruption, clathrin inhibition, G protein uncoupling); chemotaxis recovery assays on human Th2 cells\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic dissection of receptor internalization with multiple pharmacological inhibitors, comparison with CCL17, functional consequence (desensitization/recovery) established\",\n      \"pmids\": [\"14971049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Latent membrane protein 1 (LMP1) of EBV induces CCL22 expression in B cells via NF-κB and ATF2/p38 signaling pathways; transfection assays with CCL22 promoter-reporter constructs identified two NF-κB sites and one AP-1 site as required for LMP1-mediated CCL22 promoter activation.\",\n      \"method\": \"Transient transfection reporter assay with CCL22 promoter constructs; pathway inhibitors (BAY11-7082, SB202190); RT-PCR; ELISA\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — promoter dissection with reporter constructs identifying specific NF-κB and AP-1 sites, corroborated with pharmacological inhibitors, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"14747532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL22 and CCL17 stimulate T cell migration via CCR4 through a phospholipase C (PLC)- and diacylglycerol/novel PKC isoform-dependent mechanism; PLC inhibition blocks both Ca2+ mobilization and chemotaxis. Specifically, CCL22 stimulates phosphatidylinositol-3 kinase-independent phosphorylation of PKCδ at Thr505, associated with increased catalytic activity. Inhibition of IP3 receptor-mediated Ca2+ release blocks Ca2+ responses but not directional migration.\",\n      \"method\": \"Pharmacological inhibitors of PLC, PKC isoforms, IP3R, PI3K; Ca2+ imaging; chemotaxis assay in CEM cells and primary Th2 cells; PKCδ phosphorylation by western blot\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal pharmacological dissections separating Ca2+ signaling from migration, specific PKCδ phosphorylation identified, two cell systems used\",\n      \"pmids\": [\"16614259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RANKL stimulation induces CCL22 production in differentiating osteoclasts; CCL22 stimulates migration and invasion of CCR4-expressing lung cancer cells (SBC-5) and activates phosphorylation of Akt and ERK in these cells.\",\n      \"method\": \"RANKL stimulation of RAW264.7 and mouse bone marrow cells; RT-PCR; ELISA; migration assay; western blot (pAkt, pERK); immunohistochemistry of bone metastasis lesions\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RANKL identified as inducer in two osteoclast models, CCL22-stimulated Akt/ERK signaling shown in cancer cells, in vivo co-localization confirmed, single lab\",\n      \"pmids\": [\"16821125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HCMV UL144 protein activates NF-κB to transcriptionally induce CCL22; although viral IE86 can block NF-κB binding to synthetic promoters, it is unable to block UL144-mediated activation of the CCL22 promoter, with CREB binding to the CCL22 promoter implicated in this resistance.\",\n      \"method\": \"Promoter-reporter transfection assays; co-expression of UL144 and IE86; EMSA/DNA binding analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assays with specific viral proteins establish UL144/NF-κB/CCL22 axis and IE86 resistance, single lab\",\n      \"pmids\": [\"18287226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL22 promotes formation of DC–regulatory T cell contacts through CCR4 in lymph nodes; CCL22 expression by DCs is required for proper Treg–DC interaction. In CCL22-deficient mice, vaccination leads to excessive T cell responses, and tumor-bearing CCL22-deficient mice show prolonged survival upon vaccination.\",\n      \"method\": \"CCL22-deficient mouse model; vaccination assays; tumor challenge; flow cytometry; live imaging of cell-cell contacts\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model with multiple functional readouts (vaccination response, tumor survival, cell contacts), replicated in multiple experimental settings\",\n      \"pmids\": [\"30910796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL22 produced by tumor cells recruits CCR4-expressing regulatory T cells into breast tumor-associated lymphoid infiltrates; blood Tregs selectively express CCR4, and CCR4 is downregulated on tumor-infiltrating Tregs indicating receptor engagement by CCL22.\",\n      \"method\": \"Immunohistochemistry; flow cytometry; in vitro migration assay; CCR4 expression analysis on Tregs\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — migration assay plus CCR4 downregulation as evidence of in vivo engagement, correlation with CCL22 expression, single lab\",\n      \"pmids\": [\"19244125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL22 level in malignant pleural effusion is chemotactic for CD4+CD25+FoxP3+ regulatory T cells; this chemotactic activity is partially blocked by anti-CCL22 antibody but not anti-CCL17 antibody. Intrapleural administration of CCL22 induces progressive influx of Tregs into the pleural space in vivo.\",\n      \"method\": \"In vitro Transwell migration assay with neutralizing antibody; in vivo intrapleural CCL22 administration; ELISA; flow cytometry\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody neutralization in vitro and in vivo CCL22 administration both confirm direct Treg recruitment, single lab\",\n      \"pmids\": [\"19318474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In mesenteric lymph node DCs, phagocytosis of autologous apoptotic cells induces CCL22 expression; CCL22/CCR4 axis facilitates DC–Treg interactions that promote IDO expression in DCs via CTLA-4/B7. CCR4-deficient mice show markedly reduced IDO expression in MLN-DCs.\",\n      \"method\": \"CCR4-KO mouse model; apoptotic cell phagocytosis assay; IDO activity measurement; CTLA-4 conditional deletion in Tregs; colocalization analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO confirms CCL22/CCR4 requirement for IDO induction, apoptotic cell trigger identified, single lab\",\n      \"pmids\": [\"19843945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TNF-α/IFN-γ-induced CCL22 production in HaCaT keratinocytes is mediated via NF-κB and STAT1 activation, with p38 MAPK acting upstream to regulate both pathways. The adenylyl cyclase–cAMP system suppresses CCL22 production by inhibiting NF-κB activation through the p38 MAPK pathway.\",\n      \"method\": \"Western blot; RT-PCR; ELISA; pharmacological inhibitors (p38, NF-κB, cAMP analogs, adenylyl cyclase activator)\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors converging on NF-κB/p38 mechanism, single lab, two stimulation systems tested\",\n      \"pmids\": [\"19371952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL22 controls EAE development by regulating CD11b+Ly6Chi macrophage accumulation and effector function; anti-CCL22 neutralization reduces CNS macrophage infiltration and shifts macrophage cytokine expression from TNF-dominated (M1) to IL-10-dominated (M2) phenotype, both in vivo and in in vitro macrophage cultures treated with CCL22.\",\n      \"method\": \"Anti-CCL22 neutralizing antibody in EAE model; adoptive T cell transfer; flow cytometry; in vitro macrophage culture with CCL22\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro evidence for CCL22 direct action on macrophage phenotype, single lab, mechanistic follow-up in vitro\",\n      \"pmids\": [\"20940325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Islet expression of CCL22 recruits endogenous Tregs to pancreatic islets and prevents autoimmune diabetes in NOD mice; the protective effect is abrogated by CD25-specific antibody depletion of Tregs. CCL22-mediated protection increases TGF-β levels in CD4+ T cells near islets and decreases autoreactive CD8+ T cells.\",\n      \"method\": \"AAV-mediated CCL22 gene delivery to islets; Treg depletion with anti-CD25 antibody; flow cytometry; cytokine measurement\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gene delivery with specific Treg depletion control confirms CCL22→Treg recruitment as the mechanistic axis, multiple readouts, peer-reviewed high-impact journal\",\n      \"pmids\": [\"21737880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NK cells secrete CCL22 in the tumor microenvironment and are the predominant cellular source responsible for CCL22-dependent selective recruitment of CCR4+ regulatory T cells; NK cell depletion from lung tissue significantly reduces CCL22 secretion, and CCL22 neutralization reduces selective Treg recruitment.\",\n      \"method\": \"Immunomagnetic cell isolation; FACS; flow cytometry; NK cell depletion; CCL22 neutralization; migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NK depletion and CCL22 neutralization both confirm the NK→CCL22→Treg axis, multiple methods, single lab\",\n      \"pmids\": [\"19234170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCL22 production by breast tumor cells is controlled by innate immune cell-derived signals: monocyte-derived IL-1β and TNF-α, combined with IFN-γ from NK cells, drive CCL22 secretion from tumor cells. Monocyte depletion or cytokine neutralization attenuates CCL22 secretion.\",\n      \"method\": \"Co-culture of breast tumor cell lines with PBMCs; monocyte depletion; cytokine neutralization; NK cell activation assays; ELISA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — depletion and neutralization experiments identify IL-1β, TNF-α, and IFN-γ as required co-stimuli, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"21852386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TGF-β suppresses miR-34a expression, leading to enhanced CCL22 production which recruits Treg cells to facilitate immune escape in HBV-associated hepatocellular carcinoma with portal vein tumor thrombus. TGF-β–miR-34a–CCL22 forms a regulatory axis.\",\n      \"method\": \"miRNA expression profiling; miR-34a overexpression/knockdown; TGF-β stimulation; ELISA; Treg migration assay\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistatic axis established with miR-34a manipulation and TGF-β stimulation, single lab, single paper\",\n      \"pmids\": [\"22975373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-4-driven CCL22 production by local cells is required for CCR4+ Treg migration to osteolytic lesions in experimental periodontitis; CCR4-KO mice and CCL22 blockade both increase bone loss and proinflammatory cytokines. Exogenous CCL22 delivered via PLGA microparticles restores Treg migration and bone loss arrest in IL-4-KO mice that lack endogenous CCL22.\",\n      \"method\": \"CCR4-KO mice; anti-CCL22 antibody blockade; adoptive Treg transfer; PLGA microparticle CCL22 delivery in IL-4-KO mice; flow cytometry\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacological approaches (KO, blockade, adoptive transfer, exogenous delivery) all converge on IL-4/CCL22/CCR4 axis, single lab\",\n      \"pmids\": [\"25264308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Type I IFN induced by TLR or RIG-I ligands suppresses intratumoral CCL22 levels, thereby blocking Treg immigration into tumors. Stable overexpression of CCL22 abrogates the anti-tumor effects of RLR/TLR ligand treatment, confirming that CCL22 suppression is the key downstream effector of type I IFN's Treg-blocking activity.\",\n      \"method\": \"In vivo TLR/RLR ligand treatment; CCL22 stable overexpression in tumors; flow cytometry of tumor-infiltrating Tregs; ELISA\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CCL22 overexpression rescue experiment directly establishes the type I IFN → CCL22 suppression → Treg blockade mechanistic sequence, single lab\",\n      \"pmids\": [\"26432403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Cancer cell-derived IL-1α induces CCL22 production by intratumoral dendritic cells (not by cancer cells themselves); this is prevented by the IL-1 receptor antagonist anakinra or by IL-1α siRNA knockdown in tumor cells, leading to suppression of Treg migration.\",\n      \"method\": \"In vitro PBMC co-culture with tumor cells; IL-1 receptor antagonist; IL-1α siRNA knockdown; ELISA; Treg migration assay\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IL-1α identified as inducer by siRNA and anakinra blockade, paracrine mechanism to DCs established, single lab\",\n      \"pmids\": [\"27757295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL22-specific T cells recognizing a HLA-A2-restricted signal-peptide-derived epitope can kill CCL22-expressing cancer cells and acute monocytic leukemia cells in a CCL22 expression-dependent manner; spontaneous CCL22-specific T cell responses exist in cancer patients.\",\n      \"method\": \"Peptide epitope stimulation of PBMCs; cytotoxicity assay; ELISPOT; tetramer enrichment/depletion; CCL22-dependent killing validation\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CCL22 signal-peptide presentation on MHC-I established functionally, CCL22-dependent killing confirmed by expression-matched controls, single lab\",\n      \"pmids\": [\"27999757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TAM-derived TGF-β induces CCL22 expression in macrophages via c-Fos; CCL22 recruits Tregs into malignant pleural effusion; Treg-secreted IL-8 further induces TGF-β production from TAMs, creating a positive feedback immunosuppressive loop.\",\n      \"method\": \"Western blot for c-Fos; TGF-β stimulation of macrophages; CCL22 neutralization; Treg migration assay; IL-8 measurement\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — c-Fos as TGF-β downstream mediator of CCL22 expression is a specific mechanistic finding; feedback loop established by multiple ELISA/migration assays, single lab\",\n      \"pmids\": [\"30928379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"M2 macrophage-derived CCL22 promotes resistance of colorectal cancer cells to 5-FU by activating the PI3K/AKT pathway, inducing EMT, and inhibiting caspase-mediated apoptosis; neutralizing anti-CCL22 antibody abolishes these effects.\",\n      \"method\": \"M2 macrophage conditioned medium; neutralizing anti-CCL22 antibody; western blot (PI3K/AKT, EMT markers, caspase); cell migration/invasion assay; apoptosis assay\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody neutralization establishes CCL22 specificity; PI3K/AKT and EMT identified as downstream pathways, single lab\",\n      \"pmids\": [\"31114248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Constitutive CCL22 expression in secondary lymphoid organs requires T cell-derived GM-CSF: DCs alone cannot produce CCL22, but coculture with T cells or T cell supernatants induces CCL22 secretion. Rag1-/- mice (lacking T cells) have low lymphoid CCL22, restored by adoptive T cell transfer or GM-CSF administration.\",\n      \"method\": \"DC-T cell coculture; T cell supernatant fractionation; cytokine neutralization; Rag1-KO mouse with adoptive transfer; GM-CSF administration\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (coculture, KO model, adoptive transfer, cytokine reconstitution) all identify T cell GM-CSF as required inducer of DC-derived CCL22\",\n      \"pmids\": [\"32907996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Upon CD40 stimulation, GC B cells upregulate CCL22 (and CCL17); CCL22 engages CCR4 on follicular helper T (TFH) cells to attract them, promoting productive T cell help. Higher-affinity GC B cells express higher CCL22 levels, creating a feedback loop that preferentially recruits TFH help. Ablation of CCL22 (and CCL17) in B cells results in inefficient affinity maturation, reduced GC participation, and fewer bone-marrow plasma cells.\",\n      \"method\": \"Conditional B cell-specific CCL22/CCL17 knockout mice; competitive GC experiments; TFH cell imaging; GC B cell affinity analysis; plasma cell quantification\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic ablation in B cells with multiple orthogonal readouts (affinity maturation, GC participation, plasma cell output), competitive experiments in same GC, high-impact journal\",\n      \"pmids\": [\"33597749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Toxoplasma gondii effector protein GRA28 is secreted into host cell nuclei and is required for CCL22 induction in human placental cells and monocytes; parasites lacking GRA28 produce reduced CCL22 and are impaired in dissemination in vivo.\",\n      \"method\": \"GRA28 deletion mutant parasite; GRA28 nuclear localization by imaging; CCL22 ELISA in human placental cells, monocyte lines, mouse immune cells in vitro and in vivo; parasite dissemination assay\",\n      \"journal\": \"mBio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deletion of GRA28 and nuclear localization establish parasite effector-driven CCL22 induction, conserved in mouse, single lab\",\n      \"pmids\": [\"34781732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL22 acts as a potent partial agonist at ACKR4 (atypical chemokine receptor 4), recruiting β-arrestin; this was identified in a systematic screen of all 43 human chemokines using a sensitive β-arrestin recruitment assay, extending the known receptor repertoire of CCL22 beyond CCR4 and ACKR2.\",\n      \"method\": \"β-arrestin recruitment assay; systematic screen of 43 chemokines against ACKR4\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic receptor screen with β-arrestin assay identifies new receptor pairing, single lab, partial agonist designation\",\n      \"pmids\": [\"32480426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Somatic gain-of-function mutations in CCL22 are the hallmark of a subset of chronic lymphoproliferative disorder of NK cells (CLPD-NK); these mutations cause ligand-biased GPCR signaling by impairing β-arrestin recruitment to CCR4, reducing receptor internalization, resulting in increased cell chemotaxis in vitro and enhanced NK cell proliferation in vivo in transgenic IL-15 mice.\",\n      \"method\": \"Genomic sequencing; β-arrestin recruitment assay; receptor internalization assay; in vitro chemotaxis assay; in vivo transgenic mouse model\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mechanistic dissection with multiple orthogonal assays (β-arrestin, internalization, chemotaxis, in vivo) establishing gain-of-function biased GPCR signaling as the molecular mechanism\",\n      \"pmids\": [\"35513723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TAM-derived CCL22 activates diacylglycerol kinase α (DGKα) which acts as a signaling adaptor linking CCR4 to FAK; CCL22/CCR4 signaling activates intracellular Ca2+/PLC-γ1 axis to stimulate DGKα phosphorylation at Tyr335 and promotes DGKα translocation to the plasma membrane to assemble a DGKα/FAK signalosome, activating the FAK/AKT pathway.\",\n      \"method\": \"Co-immunoprecipitation; western blot (phospho-FAK, phospho-DGKα); PLC-γ1 inhibition; DGKα siRNA; Ca2+ imaging; subcellular fractionation; in vivo xenograft model with DGKα siRNA\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical reconstitution of signaling complex (DGKα/FAK), specific phosphorylation site identified, multiple orthogonal approaches, in vivo validation, single lab\",\n      \"pmids\": [\"35962191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TAM-derived CCL22 activates DGKα to produce phosphatidic acid (PA), suppressing NOX4 activity and blocking cisplatin-induced ROS overproduction; CCL22 also activates DGKα/NF-κB to upregulate ABC transporters (ABCG4, ABCA3, ABCA5), lowering intratumoral cisplatin concentration. Both mechanisms contribute to cisplatin resistance in ESCC.\",\n      \"method\": \"Lipid profiling (PA measurement); NOX4 activity assay; ROS measurement; NF-κB reporter; ABC transporter RT-PCR/western blot; DGKα siRNA cholesterol-conjugate in vivo; xenograft models\",\n      \"journal\": \"Drug resistance updates\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two mechanistic branches (NOX4/ROS and ABC transporters via NF-κB) established with multiple biochemical assays and in vivo rescue, single lab extending prior study\",\n      \"pmids\": [\"38387281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In vitro, CCL22 promotes polarization of tumor-associated macrophages (TAMs) toward the M2a macrophage phenotype (CD206high) in a cervical cancer co-culture model; CCL22 regulates CD206 expression as assessed by flow cytometry.\",\n      \"method\": \"Co-culture system; CCL22 modulation; flow cytometry for macrophage subset markers\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single in vitro co-culture system, single lab, limited mechanistic depth\",\n      \"pmids\": [\"35805111\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL22 is a CC chemokine that signals primarily through its canonical receptor CCR4 (and also through ACKR2 and ACKR4) to recruit regulatory T cells, Th2 cells, and follicular helper T cells; upon CCR4 binding it activates a PLC/diacylglycerol/PKCδ-dependent migration pathway and triggers ligand-biased receptor internalization via clathrin/lipid rafts in a β-arrestin-dependent manner; downstream CCR4 signaling engages DGKα as a signaling adaptor that assembles a DGKα/FAK signalosome to activate FAK/AKT; its expression is transcriptionally controlled by NF-κB and STAT/AP-1 sites and is constitutively driven in lymphoid organs by T cell-derived GM-CSF acting on dendritic cells; somatic gain-of-function mutations that impair β-arrestin recruitment cause biased GPCR signaling with enhanced chemotaxis underlying NK cell lymphoproliferative disease; and in germinal centers, CD40-stimulated upregulation of CCL22 by GC B cells proportional to antigen-binding affinity creates a positive-feedback circuit that focuses follicular T cell help on high-affinity clones to drive antibody affinity maturation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL22 is a CC chemokine that functions as a selective chemoattractant for chronically activated and Th2 memory CD4+ T lymphocytes, signaling through its receptor CCR4, which it shares with CCL17 [#0, #1]. CCR4 engagement triggers Ca2+ mobilization and drives directional migration through a phospholipase C/diacylglycerol/PKCδ-dependent pathway that is separable from IP3-mediated Ca2+ release [#10]. CCL22 is also a potent and rapid inducer of CCR4 internalization via lipid raft- and clathrin-dependent mechanisms that produce functional desensitization, distinguishing it from CCL17 which does not internalize the receptor [#8]. The principal in vivo role of CCL22 is to recruit CCR4+ regulatory T cells and orchestrate DC–Treg contacts: CCL22-deficient mice show exaggerated vaccination responses and improved tumor control, while CCL22 delivery recruits Tregs to autoimmune and inflammatory sites to enforce tolerance [#13, #19, #23]. This Treg-recruiting axis is repeatedly co-opted in cancer, where tumor cells, dendritic cells, NK cells, and tumor-associated macrophages are induced to secrete CCL22 by signals including IL-1, TNF-α/IFN-γ, and TGF-β, thereby drawing immunosuppressive Tregs into tumors [#14, #20, #21, #27]. CCL22 expression is transcriptionally controlled by NF-κB together with STAT/AP-1 elements and is constitutively driven in lymphoid organs by T cell-derived GM-CSF acting on dendritic cells [#4, #9, #29]. In germinal centers, CD40-stimulated upregulation of CCL22 by GC B cells in proportion to antigen affinity recruits follicular helper T cells to drive antibody affinity maturation [#30]. Downstream of CCR4 in macrophages, CCL22 engages DGKα as a signaling adaptor that assembles a DGKα/FAK signalosome to activate FAK/AKT [#34]. Somatic gain-of-function mutations in CCL22 that impair β-arrestin recruitment cause biased CCR4 signaling with reduced receptor internalization and enhanced chemotaxis, underlying a subset of chronic lymphoproliferative disorder of NK cells [#33].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that a newly cloned CC chemokine selectively attracts activated T cells defined CCL22's target-cell specificity, distinguishing it from chemokines acting on myeloid cells.\",\n      \"evidence\": \"Molecular cloning from activated macrophage cDNA with Ca2+ flux and in vitro chemotaxis across multiple leukocyte types\",\n      \"pmids\": [\"9312138\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor not yet identified\", \"Signaling pathway downstream of Ca2+ flux unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identifying CCR4 as the shared receptor for CCL22 and CCL17 and linking CCL22 to Th2 memory cells defined the receptor axis and cytokine regulation of its production.\",\n      \"evidence\": \"Ca2+ flux cross-desensitization, T cell subset chemotaxis, and cytokine stimulation of producer cells\",\n      \"pmids\": [\"9794440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling downstream of CCR4 not dissected\", \"Receptor pairing with atypical receptors unaddressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying NF-κB-dependent transcription and N-terminally truncated inactive CCL22 forms established both the inducible expression control and a post-translational negative-feedback mechanism.\",\n      \"evidence\": \"ELISA, mass spectrometry of DC supernatants, NF-κB inhibition, and polarized epithelial chemotaxis assays\",\n      \"pmids\": [\"11241286\", \"11352815\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protease generating truncated forms not identified\", \"Promoter elements not yet mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showing that CCL22 (but not CCL17) drives rapid clathrin/lipid raft-dependent CCR4 internalization and desensitization revealed ligand-biased receptor regulation that tunes chemotactic responsiveness.\",\n      \"evidence\": \"Flow cytometry internalization assays with pharmacological inhibitors and chemotaxis recovery on human Th2 cells\",\n      \"pmids\": [\"14971049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"β-arrestin dependence not directly tested at this stage\", \"Structural basis of ligand bias unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Promoter dissection identifying specific NF-κB and AP-1 sites driven by viral LMP1 defined the cis-regulatory architecture of CCL22 transcription.\",\n      \"evidence\": \"CCL22 promoter-reporter constructs with pathway inhibitors in B cells\",\n      \"pmids\": [\"14747532\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous (non-viral) activators of these sites not fully mapped here\", \"Cell-type-specific enhancer usage unaddressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Separating Ca2+ signaling from migration and identifying PKCδ Thr505 phosphorylation defined the molecular pathway converting CCR4 engagement into directional movement.\",\n      \"evidence\": \"Pharmacological dissection of PLC/PKC/IP3R/PI3K with Ca2+ imaging and chemotaxis in CEM and primary Th2 cells\",\n      \"pmids\": [\"16614259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link between PKCδ and cytoskeletal effectors not defined\", \"Connection to later DGKα/FAK signalosome not established at this time\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic loss of CCL22 in mice and Treg recruitment assays established the in vivo physiological role of CCL22 in DC–Treg contact and tolerance, with consequences for vaccination and tumor immunity.\",\n      \"evidence\": \"CCL22-deficient and CCR4-KO mouse models, vaccination, tumor challenge, IDO induction, and Treg migration assays\",\n      \"pmids\": [\"30910796\", \"19244125\", \"19318474\", \"19843945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of CCL22 versus CCL17 in vivo not fully separated\", \"Downstream tolerance mediators only partially mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that islet or NK-cell-derived CCL22 recruits Tregs to confer tissue protection established the therapeutic and tumor-microenvironment relevance of the CCL22→Treg axis.\",\n      \"evidence\": \"AAV CCL22 gene delivery with anti-CD25 Treg depletion in NOD mice and NK depletion/CCL22 neutralization in tumor models\",\n      \"pmids\": [\"21737880\", \"19234170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular source hierarchy across tissues not unified\", \"Duration and reversibility of Treg recruitment unaddressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mapping the cytokine inputs (IL-1, TNF-α, IFN-γ, TGF-β/miR-34a, type I IFN) that induce or suppress CCL22 across tumor cells, DCs, and macrophages defined the regulatory network governing intratumoral CCL22 levels.\",\n      \"evidence\": \"Co-culture, cytokine neutralization, siRNA, miR-34a manipulation, and CCL22 overexpression rescue across multiple tumor systems\",\n      \"pmids\": [\"21852386\", \"22975373\", \"26432403\", \"27757295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative weighting of inducers in human tumors unclear\", \"Single-lab findings for several individual axes\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying T cell-derived GM-CSF as the required inducer of constitutive DC-derived CCL22 and identifying ACKR4 as an additional receptor refined both the homeostatic source control and the receptor repertoire of CCL22.\",\n      \"evidence\": \"DC–T cell coculture, Rag1-KO with adoptive transfer and GM-CSF reconstitution; systematic 43-chemokine β-arrestin screen against ACKR4\",\n      \"pmids\": [\"32907996\", \"32480426\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of ACKR4 partial agonism in vivo unknown\", \"GM-CSF signaling pathway to CCL22 promoter not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"B cell-specific ablation in germinal centers showed CCL22 recruits TFH help in proportion to B cell affinity, establishing a positive-feedback circuit driving antibody affinity maturation.\",\n      \"evidence\": \"Conditional B cell CCL22/CCL17 knockout, competitive GC experiments, TFH imaging, and plasma cell quantification\",\n      \"pmids\": [\"33597749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of CCL22 alone versus combined with CCL17 not fully separated\", \"Affinity-to-CCL22 transcriptional coupling mechanism unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Biochemical reconstitution of a DGKα/FAK signalosome and discovery of β-arrestin-impairing gain-of-function mutations defined a downstream effector pathway and a disease mechanism of biased CCR4 signaling.\",\n      \"evidence\": \"Co-IP, phospho-site mapping, DGKα siRNA, and xenografts; genomic sequencing with β-arrestin, internalization, chemotaxis, and IL-15 transgenic mouse assays\",\n      \"pmids\": [\"35962191\", \"35513723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DGKα/FAK operates in T cells as in macrophages unaddressed\", \"Structural basis linking mutations to β-arrestin loss not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linking CCL22/DGKα to phosphatidic acid-mediated NOX4 suppression and NF-κB-driven ABC transporter upregulation defined a mechanism of chemoresistance downstream of CCL22 signaling.\",\n      \"evidence\": \"Lipid profiling, NOX4/ROS assays, NF-κB reporter, ABC transporter expression, and DGKα siRNA xenografts\",\n      \"pmids\": [\"38387281\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability beyond ESCC unknown\", \"Relative contribution of the two branches to resistance not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CCL22 transcriptional output is quantitatively coupled to antigen affinity in GC B cells, and whether ACKR2/ACKR4 scavenging shapes CCL22 gradients in vivo, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of CCL22–CCR4/ACKR4 complexes\", \"In vivo role of atypical receptor binding uncharacterized\", \"Mechanism coupling B cell affinity to CCL22 levels unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 8, 10, 33]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 33]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 1, 3, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 19, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR4\", \"ACKR4\", \"DGKA\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":9,"faith_pct":88.88888888888889}}